Simple Blood Test May Predict Erbitux Effectiveness

Although we know that KRAS tumor mutations limit benefit from Erbitux, about six out of ten colorectal cancer patients have normal or wild type KRAS. Yet Erbitux doesn’t work for many of them either. There may be a simple way to predict early in treatment whether Erbitux is going to help to not. Significantly more patients…  Read More